Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have earned an average rating of “Moderate Buy” from the thirteen analysts that are presently covering the firm, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $365.80.

KRYS has been the topic of several recent analyst reports. Jefferies Financial Group restated a “buy” rating and issued a $474.00 target price on shares of Krystal Biotech in a research note on Monday, July 13th. Royal Bank Of Canada began coverage on shares of Krystal Biotech in a research report on Friday, August 14th. They set an “outperform” rating and a $400.00 target price for the company. HC Wainwright lifted their price target on shares of Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a report on Tuesday, June 16th. Citigroup boosted their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings cut shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th.

Krystal Biotech Price Performance

Krystal Biotech stock opened at $350.88 on Friday. The company has a market capitalization of $10.39 billion, a PE ratio of 43.97 and a beta of 0.54. Krystal Biotech has a one year low of $158.08 and a one year high of $382.54. The business has a 50 day simple moving average of $343.68 and a 200 day simple moving average of $313.75.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating the consensus estimate of $1.70 by $0.09. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%.The business had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Equities analysts anticipate that Krystal Biotech will post 7.48 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. The trade was a 1.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Thomas sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 51,000 shares of company stock worth $17,558,270. Insiders own 13.10% of the company’s stock.

Institutional Trading of Krystal Biotech

Large investors have recently made changes to their positions in the business. Integrated Wealth Concepts LLC bought a new stake in shares of Krystal Biotech during the 2nd quarter valued at $46,000. Allworth Financial LP boosted its position in shares of Krystal Biotech by 877.1% in the 2nd quarter. Allworth Financial LP now owns 469 shares of the company’s stock worth $174,000 after purchasing an additional 421 shares during the last quarter. Nykredit A S bought a new position in shares of Krystal Biotech in the 2nd quarter worth $438,000. Corient Private Wealth LP grew its stake in shares of Krystal Biotech by 767.4% during the second quarter. Corient Private Wealth LP now owns 30,558 shares of the company’s stock worth $11,357,000 after purchasing an additional 27,035 shares during the period. Finally, HighTower Advisors LLC grew its stake in shares of Krystal Biotech by 3.9% during the second quarter. HighTower Advisors LLC now owns 2,129 shares of the company’s stock worth $791,000 after purchasing an additional 80 shares during the period. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver functional genes to targeted tissues, with an emphasis on treatments that can be administered directly to affected areas.

Krystal Biotech’s lead product is Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.